bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

Key Terms

longitudinal medical

Longitudinal describes observations or data collected from the same subjects or entities repeatedly over time, tracking how things change rather than a single snapshot. For investors it matters because longitudinal information reveals trends, persistence, and potential cause-and-effect (for example in sales, safety outcomes, or earnings), helping distinguish short-term noise from meaningful long-term shifts—like watching a plant grow rather than looking at a single photo.

flow cytometry medical

A laboratory method that uses lasers and sensors to count and analyze individual cells or tiny particles as they flow past a detector, like a high‑speed supermarket scanner that reads barcodes on each item. Investors care because flow cytometry is widely used in drug development, diagnostics and manufacturing quality control; demand for the instruments, reagents and services can signal progress in clinical programs, recurring revenue streams and adoption of new therapies or tests.

sputum medical

Sputum is the mucus and material coughed up from the lungs and airways, collected as a sample for laboratory testing. For investors, sputum matters because it is a primary clinical specimen used to diagnose respiratory infections, measure drug or vaccine effectiveness, and support regulatory evidence; the ease of collecting reliable sputum samples can affect trial outcomes, market acceptance of diagnostics and therapies, and commercial potential in respiratory health.

pulmonary nodules medical

Pulmonary nodules are small, round or oval spots found in the lungs on X-rays or CT scans; they can be scar tissue, infections, or early tumors. For investors, these findings matter because they can trigger diagnostic follow-up, treatment decisions, drug or device demand, clinical trial activity, regulatory scrutiny, and potential changes in healthcare costs or company valuations—think of a nodule like a small warning light that may or may not signal a serious engine problem.

stage 1a medical

Stage 1a is an early subcategory of cancer staging that describes a very small tumor confined to its original organ with no spread to nearby tissues or other parts of the body. For investors, knowledge that a therapy targets stage 1a disease matters because early-stage treatments often involve less complex testing, clearer approval paths, different pricing and reimbursement considerations, and a different patient population and market size—similar to selling a home smoke detector versus industrial firefighting gear.

laboratory developed test (ldt) regulatory

A laboratory developed test (LDT) is a medical diagnostic test that a single clinical laboratory designs, validates and uses in-house rather than buying from a commercial manufacturer. For investors, LDTs matter because they can drive a lab’s revenue and growth more quickly than mass-market products but also carry unique risks around accuracy, reimbursement and changing regulatory rules — think of a local bakery’s custom recipe versus a factory-made packaged product.

principal investigator medical

A principal investigator is the lead person responsible for overseeing a research project or study, ensuring it stays on track and meets its goals. In the context of investments, this role can be likened to the person in charge of a team or initiative, making key decisions and managing resources. Understanding who the principal investigator is can help investors assess the reliability and credibility of a project or research effort.

nct07168993 medical

NCT07168993 is a ClinicalTrials.gov identifier — a unique serial number assigned to a specific registered clinical trial. Think of it like a flight number that lets anyone find the trial’s protocol, enrollment status, endpoints and posted results on a public registry. Investors use this identifier to track the progress, timing and outcomes of a trial because those details can directly affect a company’s regulatory approval chances, market prospects and valuation.

Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patients

Murtha Cancer Center Research Program at Uniformed Services University of the Health Sciences provides support for longitudinal study

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on non-invasive diagnostics and early cancer detection, today announced initiation of the Company’s planned large-scale, longitudinal clinical study for CyPath® Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer.

The 2,000-patient longitudinal study is designed to evaluate the clinical performance of the CyPath® Lung flow cytometry test as a noninvasive diagnostic that uses sputum samples to detect the presence of lung cancer in high-risk individuals with existing lung nodules six millimeters (mm) to less than 30 mm in diameter identified by lung cancer screening. In an earlier clinical trial, CyPath® Lung showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients with small pulmonary nodules less than 20mm. Several recent patient case studies demonstrate the test’s ability to detect lung cancer at its curative Stage 1A.

bioAffinity Technologies expects up to 20 clinical study sites, including a dozen Department of Veterans Affairs (VA) medical centers and two of the nation’s largest military hospitals, will participate in the study. Michael J. Morris, MD, pulmonology and critical care physician at Brooke Army Medical Center, is the national Principal Investigator for the study (NCT07168993). The John P. Murtha Cancer Center Research Program (MCCRP), a research program within the Department of Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, is providing support and funding associated with the trial at several federal facilities.

Physicians currently order CyPath® Lung, a laboratory developed test (LDT) offered by bioAffinity Technologies’ subsidiary Precision Pathology Laboratory Services, for their patients with indeterminate lung nodules to determine next steps in patient care.

The longitudinal clinical trial announced today will evaluate FlowPath Lung, a research-use test that uses the same technology and follows the same procedures as CyPath® Lung. The different name is simply used to distinguish the investigational assay from the commercially available test.

“As more indeterminate pulmonary nodules are found either incidentally or by routine lung cancer screening, CyPath® Lung can fill the diagnostic gap between ‘watchful waiting’ and invasive procedures that carry risk,” said Gordon Downie, MD, PhD, Chief Medical Officer of bioAffinity Technologies. “As a result, we see growing adoption and use of CyPath® Lung by physicians and expect this longitudinal trial to provide additional evidence to support inclusion of our noninvasive test as part of the standard of care for lung cancer screening and diagnosis.”

“Initiating this study represents an important milestone for CyPath® Lung,” said Maria Zannes, President and CEO of bioAffinity Technologies. “By following patients longitudinally across multiple sites, we expect to acquire robust, real-world data that reflects how CyPath® Lung may be used to support risk assessment and clinical decision-making aligned with our objective to establish CyPath® Lung as a standard of care for evaluating patients at high-risk for early-stage lung cancer.”

The study includes participation from several federal facilities to examine the test's performance in diverse patient populations, including military service members and veterans. Patient enrollment is expected to take up to 18 months with patients followed for up to 24 months or until a definitive diagnosis of cancer or no cancer is determined.

About CyPath® Lung

CyPath® Lung is a non-invasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath® Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of CyPath® Lung to identify lung cancer in difficult-to-diagnose patients; the benefits of adding CyPath® Lung to the standard of care for evaluating indeterminate lung nodules; CyPath® Lung providing clarity when imaging and risk models are inconclusive; the ability to initiate and conduct the study as planned; challenges in patient identification, enrollment, retention, and protocol adherence; site performance and operational execution; variability in study data and outcomes; the possibility that study results do not demonstrate the anticipated performance or clinical utility; changes in standards of care, competitive developments, or technological advances; delays or difficulties in obtaining, maintaining, or expanding regulatory approvals or clearances; manufacturing, quality, supply chain, and scaling challenges; reimbursement and coverage uncertainties; the ability to obtain clinician and patient adoption; and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310050054/en/

bioAffinity Technologies

Julie Anne Overton

Director of Communications

investors@bioaffinitytech.com

Source: bioAffinity Technologies, Inc.